Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
University of Maryland, Baltimore
Study ID
NCT00003400
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • filgrastim — BIOLOGICAL
  • carmustine — DRUG
  • cisplatin — DRUG
  • melphalan — DRUG
  • vinorelbine tartrate — DRUG
  • peripheral blood stem cell transplantation — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high dose chemotherapy plus peripheral stem cell transplantation followed by combination chemotherapy in treating patients with metastatic prostate cancer that has not responded to hormone therapy.

Key Dates

Start date
Sep 30, 1998
Status verified
Oct 2019
Primary completion
Mar 31, 2000
Completion
Mar 31, 2000

Study Design

Enrollment
45 participants (estimated)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Marlene & Stewart Greenebaum Cancer Center, University of MarylandBaltimoreMaryland21201-

Find similar trials in Baltimore, MD

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Marlene & Stewart Greenebaum Cancer Center, University of Maryland· Baltimore, MD

Related Studies